1. B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. Issue 4 (29th May 2022) Authors: Zhang, Chenzhi; Li, Dandan; Xiao, Binyi; Zhou, Chi; Jiang, Wu; Tang, Jinghua; Li, Yuan; Zhang, Rongxin; Han, Kai; Hou, Zhenlin; Zhang, Linjie; Sui, Qiaoqi; Liao, Leen; Pan, Zhizhong; Zhang, Xiaoshi; Ding, Peirong Journal: Journal of immunotherapy Issue: Volume 45:Issue 4(2022) Page Start: 187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer. (1st September 2020) Authors: Hou, Zhenlin; Sun, Li; Xu, Feng; Hu, Fuqing; Lan, Jingqin; Song, Da; Feng, Yongdong; Wang, Jing; Luo, Xuelai; Hu, Junbo; Wang, Guihua Journal: Cancer letters Issue: Volume 487(2020) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer. (25th April 2022) Authors: Lin, Junzhong; Sun, Hui; Zhang, Weili; Hong, Zhigang; Lu, Zhenhai; Pan, Zhizhong; Hou, Zhenlin; Peng, Jianhong Journal: Cancer medicine Issue: Volume 11:Number 22(2022) Page Start: 4225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway. Issue 3 (4th March 2018) Authors: Ibrahim, Sidikjan; Li, Guodong; Hu, Fuqing; Hou, Zhenlin; Chen, Qianzhi; Li, Geng; Luo, Xuelai; Hu, Junbo; Feng, Yongdong Journal: Cancer biology & therapy Issue: Volume 19:Issue 3(2018) Page Start: 222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗